Abstract
Bcl-2 (B-cell lymphoma 2) family proteins have been studied intensively due to their association with cancer and other human diseases. These proteins were originally associated with the regulation of outer mitochondrial membrane integrity and apoptosis. However, there is experimental evidence that suggests that several members of this family play instrumental roles in other cellular pathways including autophagy, endoplasmic reticulum signaling, mitochondrial morphology and synaptic activity among others. Bcl-2 family proteins have been explored using diverse experimental and theoretical methods to obtain structural information that can provide valuable insight for drug development. This review is focused on computational studies related to Bcl-2 family proteins. Different strategies are described and evaluated, such as Molecular Dynamics simulations, docking, and rational drug design with the aim of demonstrating the importance of structural details of either ligands or proteins. The relevance of the knowledge obtained using these tools to drug design is discussed.
Keywords: Apoptosis, Bcl-2, bioinformatics, cancer, molecular modeling, protein–protein interaction, structure-based drug design
Current Medicinal Chemistry
Title:Computational Modeling and Simulation of the Bcl-2 Family: Paving the Way for Rational Drug Design
Volume: 19 Issue: 36
Author(s): J. L. Rosas-Trigueros, I. Ilizaliturri-Flores, C. G. Benitez-Cardoza, J. Correa-Basurto and A. Zamorano-Carrillo
Affiliation:
Keywords: Apoptosis, Bcl-2, bioinformatics, cancer, molecular modeling, protein–protein interaction, structure-based drug design
Abstract: Bcl-2 (B-cell lymphoma 2) family proteins have been studied intensively due to their association with cancer and other human diseases. These proteins were originally associated with the regulation of outer mitochondrial membrane integrity and apoptosis. However, there is experimental evidence that suggests that several members of this family play instrumental roles in other cellular pathways including autophagy, endoplasmic reticulum signaling, mitochondrial morphology and synaptic activity among others. Bcl-2 family proteins have been explored using diverse experimental and theoretical methods to obtain structural information that can provide valuable insight for drug development. This review is focused on computational studies related to Bcl-2 family proteins. Different strategies are described and evaluated, such as Molecular Dynamics simulations, docking, and rational drug design with the aim of demonstrating the importance of structural details of either ligands or proteins. The relevance of the knowledge obtained using these tools to drug design is discussed.
Export Options
About this article
Cite this article as:
L. Rosas-Trigueros J., Ilizaliturri-Flores I., G. Benitez-Cardoza C., Correa-Basurto J. and Zamorano-Carrillo A., Computational Modeling and Simulation of the Bcl-2 Family: Paving the Way for Rational Drug Design, Current Medicinal Chemistry 2012; 19 (36) . https://dx.doi.org/10.2174/0929867311209066081
DOI https://dx.doi.org/10.2174/0929867311209066081 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
HPV Pathway Profiling: HPV Related Cervical Dysplasia and Carcinoma Studies
Current Pharmaceutical Design Zoledronic Acid -a Multiplicity of Anti-Cancer Action
Current Medicinal Chemistry Proteasome Inhibitors Therapeutic Strategies for Cancer
Recent Patents on Anti-Cancer Drug Discovery Theranostic Systems and Strategies for Monitoring Nanomedicine-Mediated Drug Targeting
Current Pharmaceutical Biotechnology Matrix Metalloproteinases
Current Medicinal Chemistry Ceramidases in Hematological Malignancies: Senseless or Neglected Target?
Anti-Cancer Agents in Medicinal Chemistry Immune Checkpoints Aberrations and Malignant Mesothelioma: Assessment of Prognostic Value and Evaluation of Therapeutic Potentials
Anti-Cancer Agents in Medicinal Chemistry Pathogenesis of HIV-Associated Non-Hodgkin Lymphoma
Current HIV Research Gene Expression Signatures in Primary Immunodeficiencies: The Experience from Human Disease and Mouse Models
Current Molecular Medicine Targeting Signaling Pathways in Multiple Myeloma
Current Pharmaceutical Biotechnology Unveiling the Role of Nuclear Transport in Epithelial-to-Mesenchymal Transition
Current Cancer Drug Targets Pharmacological Activation of Protein Phosphatase 2 A (PP2A): A Novel Strategy to Fight Against Human Malignancies?
Current Medicinal Chemistry Protein Z and Ischemic Stroke
Vascular Disease Prevention (Discontinued) MicroRNAs in Chronic Lymphocytic Leukemia: An Old Disease with New Genetic Insights
MicroRNA Parkinson's Disease, Diabetes and Cognitive Impairment
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Cancer Regulator MicroRNA: Potential Relevance in Diagnosis, Prognosis and Treatment of Cancer
Current Medicinal Chemistry Pertinence of Apoptosis Markers for the Improvement of In Vitro Fertilization (IVF)
Current Medicinal Chemistry p73 as a Pharmaceutical Target for Cancer Therapy
Current Pharmaceutical Design Structure and Expression of Different Serum Amyloid A (SAA) Variants and their Concentration-Dependent Functions During Host Insults
Current Medicinal Chemistry Tumoricidal and Anti-Angiogenic Actions of Gamma-Linolenic Acid and Its Derivatives
Current Pharmaceutical Biotechnology